[go: up one dir, main page]

MA52795B1 - Dérivés de carbamoylpyridone polycycliques pour le traitement du vih - Google Patents

Dérivés de carbamoylpyridone polycycliques pour le traitement du vih

Info

Publication number
MA52795B1
MA52795B1 MA52795A MA52795A MA52795B1 MA 52795 B1 MA52795 B1 MA 52795B1 MA 52795 A MA52795 A MA 52795A MA 52795 A MA52795 A MA 52795A MA 52795 B1 MA52795 B1 MA 52795B1
Authority
MA
Morocco
Prior art keywords
sup
hiv
treatment
img
ring
Prior art date
Application number
MA52795A
Other languages
English (en)
Other versions
MA52795A (fr
Inventor
Yoshiyuki Taoda
Yuto Unoh
Original Assignee
Shionogi & Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co., Ltd filed Critical Shionogi & Co., Ltd
Publication of MA52795A publication Critical patent/MA52795A/fr
Publication of MA52795B1 publication Critical patent/MA52795B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53861,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La présente invention concerne un composé représenté par la formule (I) : <img file="imga0001.tif" frnum="0001" he="29" id="ia01" img-content="chem" img-format="tif" inline="no" orientation="portrait" pgnum="0001" wi="72"/> dans laquelle le cycle A est un hétérocycle substitué ou non substitué ; le cycle C est un cycle benzénique ou similaire ; R<sup>1</sup> est un halogène ou similaire ; R<sup>2a</sup> et R<sup>2b</sup> sont chacun indépendamment un hydrogène ou similaire ; R<sup>3</sup> est un alkyle substitué ou non substitué ou similaire ; R<sup>4</sup> est un hydrogène ou similaire ; et n est un entier de 1 à 3.
MA52795A 2018-05-31 2019-05-30 Dérivés de carbamoylpyridone polycycliques pour le traitement du vih MA52795B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018104156 2018-05-31
PCT/JP2019/021446 WO2019230858A1 (fr) 2018-05-31 2019-05-30 Dérivé de carbamoylpyridone polycyclique
EP19810498.6A EP3805220B1 (fr) 2018-05-31 2019-05-30 Dérivés de carbamoylpyridone polycycliques pour le traitement du vih

Publications (2)

Publication Number Publication Date
MA52795A MA52795A (fr) 2021-04-14
MA52795B1 true MA52795B1 (fr) 2024-09-30

Family

ID=68698918

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52795A MA52795B1 (fr) 2018-05-31 2019-05-30 Dérivés de carbamoylpyridone polycycliques pour le traitement du vih

Country Status (36)

Country Link
US (3) US11649236B2 (fr)
EP (2) EP4257137A3 (fr)
JP (2) JP7328962B2 (fr)
KR (2) KR20250002769A (fr)
CN (2) CN112513042B (fr)
AR (1) AR115455A1 (fr)
AU (2) AU2019277548B2 (fr)
BR (1) BR112020024077A2 (fr)
CA (1) CA3102063A1 (fr)
CL (1) CL2020003002A1 (fr)
CO (1) CO2020014294A2 (fr)
CR (2) CR20200644A (fr)
DK (1) DK3805220T3 (fr)
DO (1) DOP2020000221A (fr)
EA (1) EA202092921A1 (fr)
ES (1) ES2984245T3 (fr)
FI (1) FI3805220T3 (fr)
HR (1) HRP20241221T1 (fr)
HU (1) HUE068170T2 (fr)
IL (2) IL313474A (fr)
LT (1) LT3805220T (fr)
MA (1) MA52795B1 (fr)
MD (1) MD3805220T2 (fr)
MX (2) MX2020012176A (fr)
MY (1) MY198568A (fr)
PE (2) PE20210477A1 (fr)
PH (1) PH12020552000A1 (fr)
PL (1) PL3805220T3 (fr)
PT (1) PT3805220T (fr)
RS (1) RS65891B1 (fr)
SG (1) SG11202011382PA (fr)
SI (1) SI3805220T1 (fr)
SM (1) SMT202400330T1 (fr)
UA (1) UA129229C2 (fr)
WO (1) WO2019230858A1 (fr)
ZA (1) ZA202007567B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE059677T2 (hu) 2019-03-22 2022-12-28 Gilead Sciences Inc Áthidalt triciklusos karbamoilpiridon-vegyületek és ezek gyógyszerészeti alkalmazása
JP7776335B2 (ja) * 2019-11-28 2025-11-26 塩野義製薬株式会社 多環性ピリドピラジン誘導体
US20230059640A1 (en) * 2019-11-28 2023-02-23 Shionogi & Co., Ltd. Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent
EP4110783A1 (fr) 2020-02-24 2023-01-04 Gilead Sciences, Inc. Composés tétracycliques pour le traitement d'une infection par le vih
JP7407976B2 (ja) * 2020-05-21 2024-01-04 シーセン ファーマシューティカル カンパニー リミテッド 縮合環誘導体及びその薬学的用途
EP4188379A4 (fr) * 2020-07-27 2024-08-28 Merck Sharp & Dohme LLC Inhibiteurs de l'endonucléase dépendante de la coiffe polycycliques pour le traitement ou la prévention de la grippe
CA3192145A1 (fr) * 2020-09-30 2022-04-07 Gilead Sciences, Inc. Composes de carbamoylpyridone tricyclique pontes et leurs utilisations
PE20231297A1 (es) 2021-01-19 2023-08-22 Gilead Sciences Inc Compuestos de piridotriazina sustituidos y usos de estos
CN117751118A (zh) * 2021-07-30 2024-03-22 吉斯凯(苏州)制药有限公司 大环吡啶酮类化合物及其应用
TW202446773A (zh) 2022-04-06 2024-12-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024061257A1 (fr) * 2022-09-20 2024-03-28 吉斯凯(苏州)制药有限公司 Composé cétone n-hétérocyclique polycyclique et son utilisation

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1549315A4 (fr) 2002-09-11 2007-05-23 Merck & Co Inc Composes de dihydroxypyridopyrazine-1,6-diones utiles en tant qu'inhibiteurs de l'integrase du vih
MXPA05007010A (es) 2002-12-27 2005-08-18 Angeletti P Ist Richerche Bio Tetrahidro-4h-pirido[1,2-a]pirimidinas y compuestos relacionados utiles como inhibidores de la integrasa del virus de inmunodeficiencia humana.
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
EP1852434B1 (fr) 2005-02-21 2011-07-13 Shionogi Co., Ltd. Dérivé de carbamoylpyridone bicyclique ayant une activité d'inhibition de la vih intégrase
LT3372281T (lt) 2005-04-28 2021-12-10 Viiv Healthcare Company Policiklinis karbamoilpiridono darinys, turintis živ integrazės inhibitorinį aktyvumą
BRPI0617842A2 (pt) 2005-10-27 2011-08-09 Shionogi & Co composto ou um sal farmaceuticamente aceitável ou um solvato do mesmo, e, composição farmacêutica
US10065950B2 (en) 2010-02-26 2018-09-04 Japan Tobacco Inc. Substituted thiazoles as HIV integrase inhibitors
JP5766690B2 (ja) 2010-04-12 2015-08-19 塩野義製薬株式会社 インテグラーゼ阻害活性を有するピリドン誘導体
KR20140090197A (ko) 2011-10-12 2014-07-16 시오노기세야쿠 가부시키가이샤 인터그라아제 억제 활성을 갖는 폴리사이클릭 피리돈 유도체
WO2014099586A1 (fr) 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. Dérivés 4-pyridinonetriazines en tant qu'inhibiteurs de l'intégrase du vih
PH12019501848A1 (en) 2012-12-21 2020-03-02 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP2940019B1 (fr) 2012-12-27 2018-03-28 Japan Tobacco Inc. DÉRIVÉ SUBSTITUÉ DE SPIROPYRIDO[1,2-a]PYRAZINE ET SON UTILISATION MÉDICALE EN TANT QU'INHIBITEUR D'INTÉGRASE DU VIH
EP2997033B1 (fr) 2013-05-17 2017-11-15 Merck Sharp & Dohme Corp. Composés hétérocycliques tricycliques fusionnés utiles en tant qu'inhibiteurs de l'intégrase du vih
WO2014200880A1 (fr) * 2013-06-13 2014-12-18 Merck Sharp & Dohme Corp. Composés hétérocycliques tricycliques fusionnés utiles en tant qu'inhibiteurs de l'intégrase du vih
NO2865735T3 (fr) 2013-07-12 2018-07-21
WO2015006731A1 (fr) 2013-07-12 2015-01-15 Gilead Sciences, Inc. Composés de carbamoylpyridone polycyclique et leur utilisation pour le traitement des infections à vih
WO2015039348A1 (fr) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Composés hétérocycliques tétracycliques utiles comme inhibiteurs de l'intégrase du vih
TN2016000090A1 (en) 2013-09-27 2017-07-05 Merck Sharp & Dohme Substituted quinolizine derivatives useful as hiv integrase inhibitors.
WO2015089847A1 (fr) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Composés à hétérocycles spirocycliques utiles en tant qu'inhibiteurs d'intégrase du vih
WO2015199167A1 (fr) 2014-06-25 2015-12-30 日本たばこ産業株式会社 PROCÉDÉ POUR PRÉPARER UN DÉRIVÉ SUBSTITUÉ DE SPIROPYRIDO[1,2-a]PYRAZINE ET INTERMÉDIAIRE
JPWO2016027879A1 (ja) 2014-08-22 2017-06-01 塩野義製薬株式会社 インテグラーゼ阻害活性を有する多環性ピリドン誘導体
WO2016094198A1 (fr) 2014-12-09 2016-06-16 Merck Sharp & Dohme Corp. Composés hétérocycliques spirocycliques utiles comme inhibiteurs du vih
WO2016090545A1 (fr) 2014-12-09 2016-06-16 Merck Sharp & Dohme Corp. Composés hétérocycliques spirocycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
TWI695003B (zh) * 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
EP3285582B1 (fr) 2015-03-26 2020-11-11 Merck Sharp & Dohme Corp. Dérivés de quinolizine substitués par un phosphate utiles en tant qu'inhibiteurs de l'intégrase du vih
BR112017020837A2 (pt) 2015-04-02 2018-07-03 Gilead Sciences, Inc. compostos de carbamoilpiridona policíclicos e seu uso farmacêutico
WO2016187788A1 (fr) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Composés hétérocycliques tricycliques fusionnés utiles pour traiter l'infection au vih
EP3377065B1 (fr) 2015-11-17 2022-05-18 Merck Sharp & Dohme Corp. Dérivés de pyridotriazine spirocyclique utiles en tant qu'inhibiteurs de l'intégrase du vih
US10548910B2 (en) 2015-11-17 2020-02-04 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors
WO2017106071A1 (fr) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Dérivés de quinolizine spirocycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
WO2017113288A1 (fr) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Composés hétérocycliques tricycliques condensés utiles en tant qu'inhibiteurs de l'intégrase du vih
EP3548031B1 (fr) 2016-12-02 2023-07-19 Merck Sharp & Dohme LLC Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
WO2019160783A1 (fr) 2018-02-15 2019-08-22 Merck Sharp & Dohme Corp. Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
EP3784241A4 (fr) 2018-04-27 2022-01-19 Merck Sharp & Dohme Corp. Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
CN110526930B (zh) 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
US11453669B2 (en) 2018-05-31 2022-09-27 Shionogi & Co., Ltd. Polycyclic pyridone derivative
WO2019236396A1 (fr) 2018-06-05 2019-12-12 Merck Sharp & Dohme Corp. Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
CN108957755B (zh) 2018-07-27 2021-04-30 京东方科技集团股份有限公司 一种显示组件及其控制方法、平视显示器及汽车
HUE059677T2 (hu) 2019-03-22 2022-12-28 Gilead Sciences Inc Áthidalt triciklusos karbamoilpiridon-vegyületek és ezek gyógyszerészeti alkalmazása

Also Published As

Publication number Publication date
US20230227454A1 (en) 2023-07-20
AU2019277548A1 (en) 2021-01-14
KR20250002769A (ko) 2025-01-07
US20210122751A1 (en) 2021-04-29
JP7679427B2 (ja) 2025-05-19
IL313474A (en) 2024-08-01
EP4257137A2 (fr) 2023-10-11
HRP20241221T1 (hr) 2024-12-06
FI3805220T3 (fi) 2024-08-30
JPWO2019230858A1 (ja) 2021-06-24
JP2023145723A (ja) 2023-10-11
IL279051B2 (en) 2025-01-01
MX2020012176A (es) 2021-01-29
US12139489B2 (en) 2024-11-12
DOP2020000221A (es) 2021-03-15
EP3805220A4 (fr) 2022-01-05
PT3805220T (pt) 2024-08-16
PH12020552000A1 (en) 2021-09-27
DK3805220T3 (da) 2024-08-26
JP7328962B2 (ja) 2023-08-17
PE20251594A1 (es) 2025-06-16
EA202092921A1 (ru) 2021-04-07
CL2020003002A1 (es) 2021-04-16
AR115455A1 (es) 2021-01-20
AU2019277548B2 (en) 2023-12-14
LT3805220T (lt) 2024-08-26
EP3805220B1 (fr) 2024-07-31
MX2023010377A (es) 2023-09-12
CR20200644A (es) 2021-02-05
BR112020024077A2 (pt) 2021-02-09
MY198568A (en) 2023-09-05
IL279051A (en) 2021-01-31
PE20210477A1 (es) 2021-03-11
SI3805220T1 (sl) 2024-10-30
ZA202007567B (en) 2022-04-28
CR20230571A (es) 2024-01-22
EP4257137A3 (fr) 2023-11-01
CO2020014294A2 (es) 2020-12-21
EP3805220A1 (fr) 2021-04-14
UA129229C2 (uk) 2025-02-19
WO2019230858A1 (fr) 2019-12-05
CN117327072A (zh) 2024-01-02
HUE068170T2 (hu) 2024-12-28
PL3805220T3 (pl) 2024-11-04
CN112513042A (zh) 2021-03-16
CN112513042B (zh) 2023-09-29
IL279051B1 (en) 2024-09-01
ES2984245T3 (es) 2024-10-29
US20240352015A1 (en) 2024-10-24
CA3102063A1 (fr) 2019-12-05
US11649236B2 (en) 2023-05-16
SG11202011382PA (en) 2020-12-30
KR102741390B1 (ko) 2024-12-10
RS65891B1 (sr) 2024-09-30
KR20210015922A (ko) 2021-02-10
AU2024200783A1 (en) 2024-02-29
MA52795A (fr) 2021-04-14
MD3805220T2 (ro) 2024-10-31
SMT202400330T1 (it) 2024-09-16

Similar Documents

Publication Publication Date Title
MA52795B1 (fr) Dérivés de carbamoylpyridone polycycliques pour le traitement du vih
MA42795A (fr) Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d&#39;une infection par le virus du vih
EA202092923A1 (ru) Полициклическое производное пиридона
FR3087439B1 (fr) Procédé pour la préparation de 3α-hydroxy-5α-prégnan-20-one (brexanolone)
EP4495093A3 (fr) Composé polycyclique et dispositif électroluminescent organique le comprenant
MA44021A (fr) Composés antitumoraux
MA27990A1 (fr) Derives de piperazine pour le traitement d&#39;infections par le vih
MA46101A (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MA65131A1 (fr) Utilisation d&#39;un inhibiteur d&#39;ezh2 dans la préparation d&#39;un médicament pour le traitement d&#39;un lymphome à cellules t
MA41494A (fr) Composés benzoxaborole substitués en position 4 et utilisations associées
MA52946B1 (fr) Composés
MA53370B1 (fr) Procédé et intermédiaires pour la préparation de bilastine
FR3061183B1 (fr) Compose du cobalt utile comme catalyseur d&#39;hydrosilylation, de silylation deshydrogenante et de reticulation de compositions silicones
MA42781B1 (fr) Composés étheramines et leur utilisation en tant que collecteur de flottation
FR3107897B1 (fr) Dérivés de nicotinamide mononucléotides
FR3037953B1 (fr) Procede de synthese de molecules portant une fonction oxyde de nitrile
MA28117A1 (fr) Procédé pour la préparation de composés hétérocycliques à substitution N-amino
MA41885B1 (fr) Mélange d&#39;additifs
FR3071850B1 (fr) Composition d’additifs pour carburant
MX2023008250A (es) Compuestos de derivados sustituidos en 4,6 de ip4.
CA3247981A1 (fr) Composé dérivé de 1,3-benzodioxole et composition pharmaceutique le comprenant
FR3108502B1 (fr) Dérivés de nicotinamide mononucléotides dans le traitement et la prévention des infections bactériennes
CA3242313A1 (fr) Composition pharmaceutique solide
FR3060004B1 (fr) Compose organometallique ayant une fonction iminophosphorane
RU2007143501A (ru) ИМИДАЗО[1,2-a]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ, КОТОРЫЕ МОЖНО ИСПОЛЬЗОВАТЬ В КАЧЕСТВЕ ИНГИБИТОРОВ ПЕПТИДДЕФОРМИЛАЗЫ (ПДФ)